Watch out, Novartis: Eli Lilly, Boehringer Ingelheim notch broad heart failure OK for Jardiance
Eli Lilly and Boehringer Ingelheim just got the green light to go much deeper into the heart failure market with their SGLT2 inhibitor Jardiance. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
